Geeks Give Back at the GeekWire Awards: Meet three groups wielding tech for good causes
The 2023 Geeks Give Back honorees pose in the photo booth at last year’s awards in Seattle. This year, a new slate of exceptional recipients will be feted
The 2023 Geeks Give Back honorees pose in the photo booth at last year’s awards in Seattle. This year, a new slate of exceptional recipients will be feted
Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
David Y.T. Chen, MD, has been recognized as a 2024 Castle Connolly Top Doctor and named to Castle Connolly’s Top AAPI Doctors list.
In his closing remarks, Yi-Bin Chen, MD, shares his aspirations for the future of graft versus host disease management, emphasizing the need for further clinical…
High-intensity focused ultrasound produced noninferior salvage treatment-free survival vs radical prostatectomy in localized prostate cancer.
Cretostimogene grenadenorepvec elicited durable responses in high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.
Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE…
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
GeekWire co-founders Todd Bishop, left, and John Cook open the 2024 GeekWire Awards at Showbox SoDo in Seattle on Thursday. (GeekWire Photo / Kevin
Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses the diagnosis and prognosis of patients with locally advanced cutaneous squamous cell carcinoma.